Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Patented: see www.takeda.com/en-us/patents Revised: 10/2025 PRINCIPAL DISPLAY PANEL - Kit Carton - 250 IU ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] NDC 0944-4622-01 Single-dose only For Intravenous Administration After Reconstitution Only Lyophilized powder for reconstitution ADYNOVATE and diluent preassembled in BAXJECT III system Rx Only Actual potency Takeda PRINCIPAL DISPLAY PANEL - Barrel Label - 250 IU ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] For Intravenous Administration Only ADYNOVATE and diluent preassembled in BAXJECT III system Directions for use: see package insert Rx Only IU: LOT: EXP: Takeda 6521221 PRINCIPAL DISPLAY PANEL - Blister Label - 250 IU ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] NDC 0944-4622-02 Single-dose only 6521479 For Intravenous Administration Only ADYNOVATE and diluent preassembled in BAXJECT III system Do not open until time of use Do not use if packaging is opened or damaged Discard unused portion
Role of angiotensin II receptor subtype activation in cognitive function and ischaemic brain damage
Statistical Analysis Data are expressed as mean SEM
The committee backed BPC-157, MOTS-c, KPV, epitalon, and TB-500 after evaluating use cases for ulcerative colitis, wound healing, and obesity
US$ 24.81
US$ 23.66
US$ 28.75
US$ 28.20
US$ 24.09
US$ 28.77
US$ 25.66
US$ 26.01
US$ 23.52
US$ 20.08
US$ 23.43
US$ 21.35
